Skip to main content
Clinical Trials/NCT07279285
NCT07279285
Not yet recruiting
Not Applicable

The Effect of a Sugar-free-flavored-sweet-tasting-solution on Pain Associated With Dental Injections in Pediatric Patients

University of Jordan0 sites54 target enrollmentStarted: January 1, 2026Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
54
Primary Endpoint
Self-reported pain using faces pain scale-revised (FPS-r)

Overview

Brief Summary

The goal of this clinical trial is to learn whether applying a sugar-free flavored sweet solution (SFSS) before local anesthesia helps reduce injection pain in children.

The main question it aims to answer is:

Does SFSS reduce pain during dental local anesthesia compared to a placebo (plain water)? Researchers will compare the use of SFSS and a placebo to see which results in lower pain scores.

Participants will:

Receive SFSS or placebo before local anesthesia during two dental visits Have their pain measured using self-reported and observational pain scales Have their heart rate monitored during the procedure

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
6 Years to 12 Years (Child)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Children who are 6-12 years of age.
  • Children classified as ASA1 according to the American Society of Anesthesiologists.
  • Children who have positive (Class III) or definitely positive (Class IV) behavior during preoperative behavioral assessments according to the Frankl Scale.
  • Children who required bilateral local anesthesia infiltration injections on primary or permanent teeth either in the maxilla or mandible for dental treatment (different types of restoration, stainless steel crowns, pulp therapy, and extractions).
  • Children with positive consent forms (signed and approved by their parents/ legal guardians) and attended the appointment.

Exclusion Criteria

  • Children who had a history of unpleasant experiences in dental settings.
  • Children who had a history of unpleasant experience with local anesthesia injection.
  • The presence of medically or developmentally compromising conditions.

Outcomes

Primary Outcomes

Self-reported pain using faces pain scale-revised (FPS-r)

Time Frame: Immediately after local anesthetic injection

Pain intensity measured using the Faces Pain Scale - Revised (FPS-R), ranging from 0 to 10, where higher scores indicate greater pain.

Observer-reported pain using Revised Face, Legs, Activity, Cry, Consolability Scale

Time Frame: During administration of the local anesthetic injection

Pain behavior measured using the Face, Legs, Activity, Cry, Consolability - Revised (FLACC-R) Scale, scored from 0 to 10, where higher scores indicate greater pain-related distress.

Physiological-Heart Rate

Time Frame: Baseline and During Injection

Changes in heart rate measured in beats per minute (bpm); increases in heart rate indicate higher physiological arousal associated with pain

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Lamis D. Rajab

Prof

University of Jordan

Similar Trials

Completed
Not Applicable
Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy Subjects
NCT07275775InventisBio Co., Ltd100
Recruiting
Phase 3
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
NCT07266402Celldex Therapeutics240
Recruiting
Phase 1
Double-blind, randomized, placebo-controlled pilot clinical trial to evaluate the safety, tolerability and efficacy of two doses of a conditioned medium from a co-culture of M2 macrophages and fat-derived mesenchymal cells (PRS CK STORM) in the modulation of the cytokine storm for the treatment of acute respiratory distress syndrome (ARDS) caused by SARS-Cov-2, influenza A, influenza B and respiratory syncytial virus (RSV)
2023-507700-32-00Peaches Biotech S.L.50
Recruiting
Phase 1
Randomized, Double Blind, Placebo Controlled "first-in-human" Study to Assess the Safety and Tolerability of Single Ascending Intravenous Doses and Multiple Intravenous Doses of RA0127 in Healthy Young Volunteers
2023-504324-26-00Remab Therapeutics S.L.40
Completed
Phase 1
Randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of pitolisant after repeated oral ascending doses for 14 days, including the pitolisant effect on cardiac repolarization in healthy volunteers.
2023-503945-78-00Bioprojet Pharma75